A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis Clinical Trial

— OLIKOS  

Official title:

A Single-arm, Prospective, Multi-center Study to Explore Maintained Efficacy With Ofatumumab Therapy in Patients With Relapsing Multiple Sclerosis Who Discontinue Intravenously Delivered Anti-CD20 Monoclonal Antibody (aCD20 mAb) Therapy (OLIKOS)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04486716
• Other study ID #: COMB157GUS07
• Secondary ID: 111,116
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: October 19, 2020
• Est. completion date: July 31, 2024

Study information

• Verified date: March 2024
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A single arm study evaluating the continued efficacy, safety and tolerability of ofatumumab in patients with relapsing multiple sclerosis who are transitioning from aCD20 mAb therapy

Description:

This is a single-arm multi-center, study in approximately 100 participants with relapsing multiple sclerosis who were previously treated with aCD20 mAb therapy. Eligible participants will receive open label ofatumumab 20 mg subcutaneous monthly for 12 months following initial loading regimen of 20 milligrams subcutaneous doses on Days 1, 7 and 14. Assessments will include but are not limited to Magnetic Resonance Imaging (MRI) assessed for quality by central reading center, multiple Patient Reported Outcome measurements and safety assessments. Participants that do not continue onto commercial ofatumumab or another therapy within one month of the End of Study Visit must continue into the safety Follow Up phase, consisting of every 3 month visits including B cell monitoring until they are able to start on commercial ofatumumab or switch to another therapy or until their B cells are repleted defined as a B cell concentration greater than the individual participant's baseline value or greater than the lower limit of normal. All participants will have a safety follow-up phone call at 30 days post study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 111
• Est. completion date: July 31, 2024
• Est. primary completion date: December 12, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

Participants eligible for inclusion in this study must meet all of the following criteria:

1. Written informed consent must be obtained before any assessment is performed.

2. Male or female participants aged 18 to 60 years (inclusive) at screening.

3. Diagnosis of relapsing MS (RMS) according to the 2017 Revised McDonald criteria (Thompson et al. 2018), including CIS, RRMS or SPMS with disease activity as defined by (Lublin et al. 2014).

4. Disability status at Screening with an EDSS score of 0 to 5.5 (inclusive).

5. Received at least 2 courses of intravenous aCD20 mAb (loading doses are considered 1

course):

• Participants currently treated with ocrelizumab must have received (meet all three

criteria below):

1. 2 fully infused initial 300 mg ocrelizumab iv infusions 2. At least 1 fully infused 600 mg ocrelizumab iv infusions 6 months (+/- one month) 3. Last fully infused ocrelizumab dose must have occurred within 4-9 months prior to baseline •Participants currently treated with rituximab must have received (meet both criteria

below):

1. At least 2 fully infused courses of rituximab 500 mg - 1000 mg iv every 6 months (+/- one month).

1. Initial loading regimens of rituximab i.e. 500 mg - 1000 mg on day 1 and on day 15, are allowed but this is consider a single course and must be followed by additional infusion(s) every 6 months (+/- one month)

2. Last fully infused rituximab dose must have occurred within 4-9 months prior to baseline.

6. Participants discontinuing aCD20 therapy for reasons including, but not limited to:

physician/participant preference, access to commercial drug (e.g. insurance coverage issues) or for other logistical reasons (such as geographical relocation, travel, etc.) are eligible for this study. 7. Neurologically stable within 1 month prior to first study drug administration.

8. Must be able to use a smart device or have a caregiver that can assist. Exclusion Criteria: Participants meeting any of the following criteria are not eligible for inclusion in this

study:

1. Participants that have demonstrated suboptimal response to aCD20 therapy to include:

a. Signs of MRI activity, defined as = 2 active Gd+ T1 lesions, or any new or newly enlarging T2 lesions, documented within the past 6 months

• If a prior MRI within the last 6 months is not available, then new or newly enlarging T2 lesions should be considered "not documented" and the patient may continue screening b. Documented relapse while on stable, previous aCD20 treatment.
• Relapses during the first 3 months of intravenous aCD20 therapy are allowable if the participant is then relapse-free for the 12 months following the relapse while on intravenous aCD20 therapy c. Any signs of clinical worsening as measured by EDSS or any clinical measure documented within the last 6 months

2. Discontinuing aCD20 mAb therapy due to the following treatment- emergent adverse

events:

1. Severe infusion-related reactions (Grade 3 or above)

2. Recurrent infections defined as = 2 severe infections or = 3 respiratory infections or the need for = 2 courses of antibiotics since starting aCD20 therapy, if the Investigator believes this is related to therapy.

3. Decreased IgG requiring treatment with Intravenous immunoglobulin

3. Participants with primary progressive MS (Polman et al 2011) or SPMS without disease activity (Lublin et al 2014).

4. Participants meeting criteria for neuromyelitis optica (Wingerchuk et al 2015).

5. Pregnant or nursing (lactating) women

6. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for at least 6 months after stopping study medication.

7. Participants with active chronic disease (or stable but treated with immune therapy) of the immune system other than MS (e.g. rheumatoid arthritis, scleroderma, Sjögren's syndrome, Crohn's disease, ulcerative colitis, etc.) or with immunodeficiency syndrome (hereditary immune deficiency, drug-induced immune deficiency).

8. Participants with active systemic bacterial, viral or fungal infections, or known to have acquired immunodeficiency syndrome (AIDS).

9. Participants with neurological symptoms consistent with PML or with confirmed PML.

10. Participants at risk of developing or having reactivation of syphilis or tuberculosis

11. Participants at risk of developing or having reactivation of hepatitis.

12. Have received any live or live-attenuated vaccines (including for varicella-zoster virus or measles) within 4 weeks prior to first study drug administration. a. There is presently no contraindication for the use of an inactivated, viral-vector-or mRNA based Sars-CoV-2 vaccine in patients who are immunocompromised. However, different Sars-CoV-2 vaccines may have various mechanisms of action and different associated potential risks. Please review local prescribing information of any specific Sars-CoV-2 vaccine and comply with local prescribing information requirements for specific contra-indications and special warnings and precautions for use.

Related Conditions & MeSH terms

• Multiple Sclerosis
• Relapsing Multiple Sclerosis
• Sclerosis

Intervention

Drug:
• Ofatumumab
Investigational drug will be provided in an autoinjector for subcutaneous administration containing 20 mg ofatumumab (20 mg/0.4 ml)

Locations

Country	Name	City	State
Puerto Rico	Caribbean Center for Clinical Research, Inc. .	Guaynabo
United States	UC Health Neuroscience Ctr	Aurora	Colorado
United States	Alabama Neurology Associates PC Suite 105	Birmingham	Alabama
United States	Beth Israel Deaconess Medical Cente	Boston	Massachusetts
United States	Parkland Health and Hospital Systems	Dallas	Texas
United States	Neurology Center of New England PC .	Foxboro	Massachusetts
United States	Infinity Clinical Research LLC	Hollywood	Florida
United States	Hope Neurology .	Knoxville	Tennessee
United States	Cleveland Clinic Foundation	Las Vegas	Nevada
United States	Ms Ctr Of Northeastern Ny	Latham	New York
United States	International Neurorehab Institute	Lutherville	Maryland
United States	Ctr for Neurology and Spine	Phoenix	Arizona
United States	Minnesota Center Multiple Sclerosis	Plymouth	Minnesota
United States	Neuro Center	Pomona	California
United States	Central TX Neuro Consultants P A .	Round Rock	Texas
United States	Swedish Neuroscience Institute MS Center	Seattle	Washington
United States	AMO Corporation .	Tallahassee	Florida
United States	University of South Florida .	Tampa	Florida
United States	Dragonfly Research LLC Elliott Lewis Center	Wellesley	Massachusetts
United States	Columbus Neuroscience Columbus Neuroscience LLC	Westerville	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Puerto Rico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with no change or reduction in gadolinium enhancing lesions at 12 months	Magnetic Resonance Imaging (MRI) will be used to measure presence of new or reduction in number of gadolinium enhancing lesions. Each MRI scan will be previewed by a local neuroradiologist. The quality of each scan performed will be assessed by a central MRI reading center and evaluated for quality, completeness and adherence to the protocol.	Baseline up to 12 months
Secondary	Change from baseline for total CD19+ B cell counts and CD3+CD20+ T cell counts,	Total CD19+ B cell counts cell counts, obtained by fluorescence activated cell sorting	Baseline up to 6 and 12 months
Secondary	Change from baseline for CD3+CD20+ T cell counts,	CD3+CD20+ T cell counts, obtained by fluorescence activated cell sorting	Baseline up to 6 and 12 months
Secondary	Change from baseline for Treatment Satisfaction Questionnaire for Medication (TSQM-9)	The Treatment Satisfaction Questionnaire for Medication (TSQM-9) will be used to evaluate the participants' satisfaction with Ofatumumab. The TSQM-9 is a psychometrically sound and valid participant reported outcome to measure participants' satisfaction with medication and a good predictor of adherence across different types of medication and participant population. The TSQM-9 is a 9 item questionnaire having a global satisfaction score ranging from 0-100. The questionnaire consists of 3 domains: satisfaction, convenience and effectiveness (3 items each). The domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain.	Baseline up to 6 and 12 months
Secondary	Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)	The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent).	Baseline up to 6 and 12 months
Secondary	Number of participants with treatment emergent adverse events	Adverse event monitoring should be continued following the last dose of study treatment until B cells are repleted. Repletion is defined as a concentration > the participant's baseline value or > the lower limit of normal, whichever is observed first.	Baseline up 13 months (includes 30 day followup) or up to 21 months for patients entering extra safety follow-up